Statins in cardiovascular diseases. What cholesterol? Which statin? What dosage? How long? Review article
Article Sidebar
Main Article Content
Abstract
Clinical trials proved efficacy of statin therapy in reduction of cardiovascular events in secondary as well as primary prevention. Due to current guidelines there is trend to reach low levels of lipids, what is particularly effective in high risk patients. Recent trails have shown safety of statin long-term therapy as well as potential ex-cardiac effects. There are still remaining questions which statin and what dosage should be used. This article summarizes current knowledge on statin therapy in cardiovascular diseases.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Eksperci Europejskiego Towarzystwa Kardiologicznego do spraw postępowania w stabilnej dławicy piersiowej: Wytyczne postępowania w stabilnej dławicy piersiowej. Kardiol. Pol. 2006; 64: 823-880.
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
5. Wiviott, S.D., de Lemos J.A., Cannon C.P. et al.: A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006; 113: 1406-1414.
6. Davidson M.H., Robinson J.G.: Safety of aggressive lipid management. J. Am. Coll. Cardiol. 2007 May 1; 49(17): 1753-62.
7. Schoenhagen P., Tuzcu E.M., Apperson-Hansen C. et al.: Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 2006 Jun 20; 113(24): 2826-34.
8. Strandberg T.E., Pyorala K., Cook T.J. et al.: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364(9436): 771-7.